Jennifer Spokes Johansson joined Larimar Therapeutics in December 2016 as Vice President, Regulatory Affairs and Counsel, bringing more than 20 years of pharmaceutical legal and regulatory experience to the company. Most recently, Ms. Johansson served as senior vice president, regulatory policy and counsel for Putney (acquired by Dechra), an early stage veterinary generics company. While at Putney from company initiation through exit, she was chair of the Generic Animal Drug Alliance and a member of the industry negotiation teams for the Animal Generic Drug User Fee Act and its reauthorization. Prior to Putney, Ms. Johansson served as vice president of regulatory affairs, as well as counsel, for Andrx (now Teva), a human drug company focused on generics and pharmaceutical delivery. Before joining Andrx, she was an associate in a leading food and drug regulatory practice at the law firm of Patton Boggs (now Squire Patton Boggs) in Washington, DC. Ms. Johansson started her career in laboratory research at the National Institutes of Health. Ms. Johansson graduated with an AB, cum laude with Distinction in Biology from Duke University and holds a JD, magna cum laude, from Boston University School of Law, where she was an editor of the Boston University Law Review. She is a member of the bars of Massachusetts and Washington, DC.